Astellas’ Once-Daily Tacrolimus Again “Approvable” For Kidney Transplant Patients
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma received a second U.S. FDA "approvable" letter for use of its long-lasting immunosuppressant FK506 in kidney transplant patients, the company said March 14.